Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Maplirpacept by Pfizer for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Maplirpacept is under clinical development by Pfizer and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....
Marstacimab by Pfizer for Hemophilia B (Factor IX Deficiency): Likelihood of Approval
Marstacimab is under clinical development by Pfizer and currently in Pre-Registration for Hemophilia B (Factor IX Deficiency). According to GlobalData,...
Sisunatovir hydrochloride by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
Sisunatovir hydrochloride is under clinical development by Pfizer and currently in Phase III for Respiratory Syncytial Virus (RSV) Infections. According...
Etrasimod by Pfizer for Eosinophilic Esophagitis: Likelihood of Approval
Etrasimod is under clinical development by Pfizer and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II...
Binimetinib by Pfizer for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Binimetinib is under clinical development by Pfizer and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
PF-07261271 by Pfizer for Inflammatory Bowel Disease: Likelihood of Approval
PF-07261271 is under clinical development by Pfizer and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase...
Sasanlimab by Pfizer for Ovarian Cancer: Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
Sasanlimab by Pfizer for Solid Tumor: Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Sasanlimab by Pfizer for Sarcomas: Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs...
PF-07831694 by Pfizer for Clostridioides difficile Infections (Clostridium difficile Associated Disease): Likelihood of Approval
PF-07831694 is under clinical development by Pfizer and currently in Phase II for Clostridioides difficile Infections (Clostridium difficile Associated Disease)....
Inotuzumab ozogamicin by Pfizer for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Inotuzumab ozogamicin is under clinical development by Pfizer and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
Inclacumab by Pfizer for Sickle Cell Disease With Vaso-Occlusive Crisis: Likelihood of Approval
Inclacumab is under clinical development by Pfizer and currently in Phase III for Sickle Cell Disease With Vaso-Occlusive Crisis. According...
Elranatamab by Pfizer for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Elranatamab is under clinical development by Pfizer and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData,...
Inotuzumab ozogamicin by Pfizer for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval
Inotuzumab ozogamicin is under clinical development by Pfizer and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid...
PF-06425090 by Pfizer for Clostridioides difficile Infections (Clostridium difficile Associated Disease): Likelihood of Approval
PF-06425090 is under clinical development by Pfizer and currently in Phase III for Clostridioides difficile Infections (Clostridium difficile Associated Disease)....
Risk adjusted net present value: What is the current valuation of Pfizer's Maplirpacept?
Maplirpacept is a fusion protein commercialized by Pfizer, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...
Risk adjusted net present value: What is the current valuation of Pfizer's Inclacumab?
Inclacumab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease With Vaso-Occlusive...
Risk adjusted net present value: What is the current valuation of Pfizer's Sisunatovir Hydrochloride?
Sisunatovir Hydrochloride is a small molecule commercialized by Pfizer, with a leading Phase III program in Respiratory Syncytial Virus (RSV)...
Risk adjusted net present value: What is the current valuation of Pfizer's Giroctocogene fitelparvovec?
Giroctocogene fitelparvovec is a gene therapy commercialized by Pfizer, with a leading Phase III program in Hemophilia A (Factor VIII...
Risk adjusted net present value: What is the current valuation of Pfizer's PF-06835375?
PF-06835375 is a biologic commercialized by Pfizer, with a leading Phase II program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....